211 related articles for article (PubMed ID: 11062088)
1. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
2. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
3. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
4. [The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
Chiti A; Spinelli A; Bombardieri E
Radiol Med; 1997 Oct; 94(4):362-70. PubMed ID: 9465244
[No Abstract] [Full Text] [Related]
5. Biodistribution of 111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden.
Adrian HJ; Dörr U; Bach D; Bihl H
Horm Metab Res Suppl; 1993; 27():18-23. PubMed ID: 8330868
[TBL] [Abstract][Full Text] [Related]
6. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
Pauwels S; Leners N; Fiasse R; Jamar F
Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
[No Abstract] [Full Text] [Related]
7. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
8. [Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
Mure A; Lebtahi R; de Labriolle-Vaylet C; Askienazy S
Gastroenterol Clin Biol; 1998 Oct; 22(10):809-18. PubMed ID: 9854206
[No Abstract] [Full Text] [Related]
9. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.
Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; Reubi JC; Lamberts SW
Ann N Y Acad Sci; 1994 Sep; 733():416-24. PubMed ID: 7978890
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor imaging in patients with neuroendocrine tumors: preoperative and postoperative scintigraphy and intraoperative use of a scintillation detector.
Ahlman H; Tisell LE; Wängberg B; Nilsson O; Forssell-Aronsson E; Fjälling M
Semin Oncol; 1994 Oct; 21(5 Suppl 13):21-8. PubMed ID: 7992076
[No Abstract] [Full Text] [Related]
12. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].
Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO
Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors].
Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M
Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
[TBL] [Abstract][Full Text] [Related]
15. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.
Forssell-Aronsson E; Fjälling M; Nilsson O; Tisell LE; Wängberg B; Ahlman H
J Nucl Med; 1995 Jan; 36(1):7-12. PubMed ID: 7799086
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
[TBL] [Abstract][Full Text] [Related]
17. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.
John M; Meyerhof W; Richter D; Waser B; Schaer JC; Scherübl H; Boese-Landgraf J; Neuhaus P; Ziske C; Mölling K; Riecken EO; Reubi JC; Wiedenmann B
Gut; 1996 Jan; 38(1):33-9. PubMed ID: 8566856
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]